Crossmark

Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital

Crossref DOI link: https://doi.org/10.1007/s10067-022-06166-3

Published Online: 2022-04-11

Published Print: 2022-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Suga, Takeshi

Oiwa, Hiroshi https://orcid.org/0000-0001-8924-8616
Ishida, Michihiro

Iwamoto, Yasuo
License Information

Text and Data Mining valid from 2022-04-11

Version of Record valid from 2022-04-11
More Information

Article History

Received: 20 January 2022

Revised: 18 February 2022

Accepted: 3 April 2022

First Online: 11 April 2022

Compliance with ethical standard

:

: This study complied with the Declaration of Helsinki, and the institutional review board of Hiroshima City Hiroshima Citizens Hospital approved this study (approval no. 2021–101). The need to obtain informed consent from patients was waived in accordance with the regulations for retrospective cohort studies. Information for patients regarding this study was provided on the hospital website.

: None.

Document is current

Any future updates will be listed below